Home
About Us
Company Profile
Enterprise Honor
Enterprise Qualification
Corporate Shareholder
Science & Innovation
Molecular Glue
GLUETAC
Degrader-Antibody Conjugates
Journal Articles
Pipeline
GT919
GT929
GT818
GT820
Partnerships
Local Cooperation
Out Licensing
Global Cooperation
University Cooperation
Subject Recruitment
Multiple myeloma
Non-Hodgkin’s lymphoma
Talent Strategy
Talent concept
Employee honor
Employee Showcase
Welfare system
Job Openings
Talent scheme
Press Releases
R&D advancements
Technology Platform
Media Coverage
Contact Us
China
USA
Canada
Home
About Us
Company Profile
Enterprise Honor
Enterprise Qualification
Corporate Shareholder
Science & Innovation
Molecular Glue
GLUETAC
Degrader-Antibody Conjugates
Journal Articles
Pipeline
GT919
GT929
GT818
GT820
Partnerships
Local Cooperation
Out Licensing
Global Cooperation
University Cooperation
Subject Recruitment
Multiple myeloma
Non-Hodgkin’s lymphoma
Talent Strategy
Talent concept
Employee honor
Employee Showcase
Welfare system
Job Openings
Talent scheme
Press Releases
R&D advancements
Technology Platform
Media Coverage
Contact Us
China
USA
Canada
中文
English
中文
English
Slide 1
Technology-driven
Pioneering
Devoted to patients
News
center
More...
24
2024-09
GLUETACS co-published a research paper on BCL-xL degrader displaying synergistic antitumor effects on hepatocellular carcinoma
11
2024-09
Gluetacs Therapeutics was selected for the Huayi 2024 China Biopharmaceutical Technology Innovation Value List Top 10 Small Molecule Innovative Drug Companies with the Most Growing Potential
16
2024-07
Linkage between government and enterprise, Biologic won the “Service package” of key enterprises in Lingang New Area in 2024
21
2024-06
Gluetacs Co-publishes Cover Article in CELL
Sub-Journal Reporting NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers
04
2024-06
Gluetacs won the 2022 6th Medical Health Investment Excellence Ranking List for the annual biomedical industry
31
2024-05
Gluetacs Therapeutics completed a round of financing to accelerate the clinical transformation of protein-degrading drugs
30
2024-05
Conference Preview|Gluetacs to Present at Biotechnology in America 2024 (BIO)